✦ LIBER ✦

The antimicrobial effect of Iseganan HCl oral solution in patients receiving stomatotoxic chemotherapy: analysis from a multicenter, double-blind, placebo-controlled, randomized, phase III clinical trial

✍ Scribed by Sharon Elad; Joel B. Epstein; Judith Raber-Durlacher; Peter Donnelly; Jacob Strahilevitz

Book ID: 111255553
Publisher: John Wiley and Sons
Year: 2011
Tongue: English
Weight: 216 KB
Volume: 41
Category: Article
ISSN: 0904-2512
DOI: 10.1111/j.1600-0714.2011.01094.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase 3 randomized, placebo-controlled

A phase 3 randomized, placebo-controlled, double-blind, clinical trial of the effect of modafinil on cancer-related fatigue among 631 patients receiving chemotherapy : A University of Rochester Cancer Center Community Clinical Oncology Program Research base study

✍ Pascal Jean-Pierre; Gary R. Morrow; Joseph A. Roscoe; Charles Heckler; Supriya M 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB 👁 1 views

A phase III randomized double-blind plac

A phase III randomized double-blind placebo-controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation

✍ Mark M. Schubert; Fernanda P. Eduardo; Katherine A. Guthrie; Jean-Claude Franqui 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 304 KB

A phase II, multicenter, randomized, dou

A phase II, multicenter, randomized, double-blind, placebo-controlled trial of the safety and efficacy of velafermin (CG53135-05) administered intravenously as a single dose for the prevention of oral mucositis in patients receiving autologous hematopoietic stem cell transplant (AHSCT)

✍ E. Anaissie; M.W. Schuster; D. Hurd; W. Bensinger; J. Mason; J.M. McCarty; R. Ri 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 64 KB

Randomized, Double-Blind, Placebo-Contro

Randomized, Double-Blind, Placebo-Controlled, Phase III Cross-Over Study Evaluating the Oral Neurokinin-1 Antagonist Aprepitant in Combination With a 5HT3 Receptor Antagonist and Dexamethasone in Patients With Germ Cell Tumors Receiving 5-Day Cisplatin Combination Chemotherapy Regimens: A Hoosier Oncology Group Study

✍ Albany, C.; Brames, M. J.; Fausel, C.; Johnson, C. S.; Picus, J.; Einhorn, L. H. 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 156 KB

Abstract of the 20th International Anniv

Abstract of the 20th International Anniversary MASCC/ISOO Symposium: A Phase III randomized double-blind placebo controlled clinical trial to determine the efficacy of low level laser therapy for the prevention of oral mucositis in patients undergoing hematopoietic cell transplantation

✍ M. M. Schubert; F. P. Eduardo; K. A. Guthrie; J. C. Franquin; R. J. Bensadoun; C 📂 Article 📅 2007 🏛 Springer-Verlag 🌐 English ⚖ 64 KB

3010 ORAL Final overall survival (OS) re

3010 ORAL Final overall survival (OS) results of CONFIRM 1 (CF1), a randomized, double-blind, placebo-controlled phase III trial in patients with metastatic adenocarcinoma of the colon or rectum (mCRC) receiving first line chemotherapy with oxaliplatin/5-fluorouracil/Leucovorin (FOLFOX 4) and PTK787/ZK 222584 (PTK/ZK) or placebo (PBO)

✍ J.R. Hecht; T. Trarbach; E. Jaeger; J. Hainsworth; R.A. Wolff; K. Lloyd; G. Bodo 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 58 KB